Recorded 04/23/25

TD Cowen analyst Yaron Werber speaks with John Crowley to discuss his inspirational path to becoming a biotech CEO, taking the helm at BIO, the implications of potential biopharma tariffs and his conversations with the White House on finding common ground, and maintaining optimism despite the headwinds facing biotech. He shares his views on why he does not think the proposed tariffs will end up as the final rule, why the Biosecure Act failed to pass Congress, and why he is optimistic that current changes at FDA provide a window of opportunity to expediting drug approvals. John also notes the importance of being "fundamentally optimistic" and "unbelievably resilient" to weather the ever-challenging environment of biotech.

https://go.td.com/PodcastDisclosure